原发性肝癌患者血清α-L-岩藻糖苷酶、糖类抗原724、糖类抗原19-9水平与临床病理特征的相关性分析  

Correlation Analysis of Serumα-L-fucosidase,Carbohydrate Antigen 724,and Carbohydrate Antigen 19-9 Levels with Clinical Pathological Characteristics in Patients with Primary Liver Cancer

作　　者：于兆亚 张孟伟 陈栋 卢伟伟 YU Zhao-ya;ZHANG Meng-wei;CHEN Dong;LU Wei-wei(Department of Laboratory Medicine,Huaihe Hospital,Henan University,Kaifeng 475000,Henan Province,China)

机构地区：[1]河南大学淮河医院检验科,河南开封475000

出　　处：《罕少疾病杂志》2024年第9期74-76,共3页Journal of Rare and Uncommon Diseases

基　　金：2020年度河南省医学科技攻关计划(LHGJ20200558)。

摘　　要：目的 分析原发性肝癌(PHC)患者血清α-L-岩藻糖苷酶(AFU)、糖类抗原724(CA724)、糖类抗原19-9(CA19-9)水平与临床病理特征的相关性。方法 我院2021年3月至2023年1月收治的71例PHC患者为PHC组,71例同期肝硬化患者为对照组。比较两组入院时血清AFU、CA724、CA19-9水平及不同临床病理参数的血清AFU、CA724、CA19-9水平;并分析其相关性;采用ROC进行相关分析。结果 研究组血清AFU、CA724、CA19-9水平高于对照组(t1=15.782;t2=14.195;t3=18.504,P<0.05);不同病理学参数PHC患者血清AFU、CA724、CA19-9水平比较:肿瘤数目(单发)低于肿瘤数目(多发)(t1=5.531;t2=8.155;t3=4.937,P<0.05);肿瘤直径(≤5cm)低于肿瘤直径(>5cm)(t1=7.333;t2=11.808;t3=9.026,P<0.05);Ⅰ~Ⅱ期低于Ⅲ~Ⅳ期(t1=12.733;t2=15.329;t3=15.623,P<0.05);低分化高于中高分化(t1=13.450;t2=26.847;t3=17.349,P<0.05);无淋巴结转移低于有淋巴结转移(t1=14.745;t2=33.192;t3=16.148,P<0.05);入院时血清AFU、CA724、CA19-9水平与分化程度呈负相关,与肿瘤直径、肿瘤数目、淋巴结转移、临床分期呈正相关(P<0.05);入院时血清AFU、CA724、CA19-9水平联合检测PHC的AUC为0.878(95%CI:0.857~0.890,P<0.05)。结论 血清AFU、CA724、CA19-9水平与PHC关系密切,可作为临床诊断的辅助参考指标。Objective To analyze the correlation between serumα-L-fucosidase(AFU),carbohydrate antigen 724(CA724),carbohydrate antigen 19-9(CA19-9)levels and clinicopathological features in patients with primary hepatoearcinoma(PHC).Methods A total of 71 patients with PHC admitted to our hospital from March 2021 to January 2023 were selected as the PHC group,and 71 patients with cirrhosis during the same period served as the control group.The levels of serum AFU,CA724 and CA19-9 in two groups at admission were compared with those in different clinical pathological parameters;and analyze their correlation;Correlation analysis was performed using ROC.Results Serum levels of AFU,CA724 and CA19-9 in the study group were higher than those in the control group(t1=15.782;t2=14.195;t3=18.504,P<0.05);comparison of serum AFU,CA724 and CA19-9 levels in patients with PHC with different pathological parameters:the number of tumors(single)was lower than that of tumors(multiple)(t1=5.531;t2=8.155;t3=4.937,P<0.05).Tumors with a diameter of≤5cm were smaller than those exceeding 5cm(t1=7.333;t2=11.808;t3=9.026,P<0.05).StageⅠ-Ⅱwas lower than StageⅢ-Ⅳ(t1=12.733;t2=15.329;t3=15.623,P<0.05).Low differentiation was higher than medium and high differentiation(t1=13.450;t2=26.847;t3=17.349,P<0.05).The rate of lymph node metastasis in patients without lymph node metastasis was lower than that in patients with lymph node metastasis(t1=14.745;t2=33.192;t3=16.148,P<0.05).The levels of serum AFU,CA724,and CA19-9 at admission were negatively correlated with the degree of differentiation,and positively correlated with tumor diameter,tumor number,lymph node metastasis,and clinical stage(P<0.05).The AUC of serum AFU,CA724 and CA19-9 combined at admission was 0.878(95%CI:0.857-0.890,P<0.05).Conclusion Serum levels of AFU,CA724 and CA19-9 are closely related to PHC,which can be used as auxiliary reference indexes in clinical diagnosis.

关 键 词：Α-L-岩藻糖苷酶 糖类抗原724 糖类抗原19-9 病理特性 原发性肝癌 

分 类 号：R363[医药卫生—病理学] R735.7[医药卫生—基础医学]